Rock Creek Group’s VistaGen Therapeutics VTGN Stock Holding History

Rock Creek Group’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,386	Closed	-$263K	–	224
2021 Q4	$263K	Buy	+5,386	New	+$351K	0.04%	127

Other funds holding VTGN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NIP

Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

Rock Creek Group's VTGN Position: Q1 2022 in Review

Rock Creek Group sold out of VistaGen Therapeutics (VTGN) in Q1 2022, closing a stake of 5,386 shares — an estimated $263K sold.

Rock Creek Group first reported a position in VTGN in Q4 2021 and held it in 1 quarter. The position peaked at $263K in Q4 2021. 116 funds tracked by Wall St. Rank hold VTGN as of Q1 2022.

Rock Creek Group reported no remaining VistaGen Therapeutics position as of Q1 2022 after selling out during the quarter.
Rock Creek Group sold 5,386 VistaGen Therapeutics shares in Q1 2022, an estimated $263K.
Rock Creek Group first reported a position in VistaGen Therapeutics in Q4 2021 and held it in 1 quarter.
Rock Creek Group's VistaGen Therapeutics position peaked at $263K in Q4 2021.
116 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2022.

Based on Rock Creek Group's 13F filing for Q1 2022, filed 11 May 2022.